Iovance Biotherapeutics (FRA:2LB) Net Interest Income : €12.66 Mil (TTM As of Sep. 2024)

View and export this data going back to 2015. Start your Free Trial

What is Iovance Biotherapeutics Net Interest Income?

Net interest income is the total interest income minus total interest expense. It represents the difference between interest and dividends earned on interestbearing assets and interest paid to depositors and other creditors. Iovance Biotherapeutics's net interest income for the three months ended in Sep. 2024 was €3.61 Mil. Its net interest income for the trailing twelve months (TTM) ended in Sep. 2024 was €12.66 Mil.

Iovance Biotherapeutics Net Interest Income Historical Data

The historical data trend for Iovance Biotherapeutics's Net Interest Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Iovance Biotherapeutics Net Interest Income Chart

Iovance Biotherapeutics Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Net Interest Income

Get a 7-Day Free Trial

8.38

1.94

0.40

2.82

11.96

Iovance Biotherapeutics Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
Net Interest Income	Get a 7-Day Free Trial															3.15	2.86	3.07	3.12	3.61

Iovance Biotherapeutics Net Interest Income Calculation

Net Interest Income for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €12.66 Mil.

Iovance Biotherapeutics Net Interest Income Related Terms

Thank you for viewing the detailed overview of Iovance Biotherapeutics's Net Interest Income provided by GuruFocus.com. Please click on the following links to see related term pages.

Iovance Biotherapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Iovance Biotherapeutics Inc (FRA:2LB) » Definitions » Net Interest Income

Comparable Companies

Traded in Other Exchanges

IOVA:USA 0JDK:UK 2LB:Germany

Address

825 Industrial Road, Suite 400, San Carlos, CA, USA, 94070

Website

https://www.iovance.com

Iovance Biotherapeutics Inc is a clinical-stage biopharmaceutical company, pioneering a transformational approach to treating cancer by harnessing the human immune system's ability to recognize and destroy diverse cancer cells using therapies personalized for each patient. The company is preparing for potential U.S. regulatory approvals and commercialization of the first autologous T-cell therapy to address a solid tumor cancer. its objective is to be the leader in innovating, developing, and delivering tumor-infiltrating lymphocyte, or TIL, therapies for patients with solid tumor cancers.

Iovance Biotherapeutics Headlines

No Headlines